Eleksakaftor, tezakaftor ve ivakaftor etkileşimleri

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Avoid food or drink containing grapefruit. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Lumacaftor/Ivacaftor Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

…delayed offset of the recently discontinued CYP3A inducer [see Drug Interactions (7.3) ] : • Anticancer drugs: apalutamide, enzalutamide • Anticonvulsant: carbamazepine, phenobarbital, primidone, phenytoin • Antimycobacterials: rifampin, rifapentine • Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor • Herbal products: St. (Nirmatrelvir ve ritonavir etiketi, Kontrendikasyonlar)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Patients with elevated vitamin A levels may be at increased risk. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Patients with elevated vitamin A levels may be at increased risk. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Patients with elevated vitamin A levels may be at increased risk. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Transporters Concomitant use of ivacaftor or tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin AUC by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant use of fluconazole increased ivacaftor AUC by 2.9-fold [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Patients with elevated vitamin A levels may be at increased risk. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

When used concomitantly with itraconazole and ketoconazole, ivacaftor AUC increased by 15.6-fold and 8.5-fold, respectively [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

John's wort ( Hypericum perforatum ) Strong or Moderate CYP3A Inhibitors The dosage of TRIKAFTA should be reduced when used concomitantly with strong CYP3A inhibitors [see Dosage and Administration (2.4) and Warnings and Precautions (5.6) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Patients with elevated vitamin A levels may be at increased risk. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Examples of strong CYP3A inducers include: rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Drugs with No Clinically Significant Interactions with TRIKAFTA Ciprofloxacin Ciprofloxacin had no clinically relevant effect on the exposure of tezacaftor or ivacaftor and is not expected to affect the exposure of elexacaftor. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)